TSE:2212
TSE:2212Food

Is There Room for Further Gains in Yamazaki Baking After 22% Jump in 2024?

Thinking about what to do with your Yamazaki Baking shares? You are not alone. With the stock up 22.1% in the past year and an impressive 115.4% gain over three years, investors are understandably curious about whether there is more room to rise, or if recent price strength is running out of steam. After all, the stock's seven-day dip of -0.8% and a slightly negative return in the past month might point to some cautious re-evaluation in the market. However, if you zoom out, Yamazaki Baking’s...
NasdaqGM:FEIM
NasdaqGM:FEIMElectronic

A Fresh Look at Frequency Electronics (FEIM) Valuation Following $20 Million Buyback and Quantum Expansion

If you have been following Frequency Electronics (FEIM), you probably noticed the company just announced a fresh $20 million share repurchase program, coming right on the heels of its first quarter earnings. This move suggests leadership is signaling a lot of confidence in the company's long-term prospects, even as quarterly results came in below expectations. Alongside this buyback, management also highlighted recent expansion in quantum sensing technology and an engineering facility in...
TSE:1861
TSE:1861Construction

Is Kumagai Gumi on Solid Ground After Its 49% Jump and Infrastructure Spending Boost?

If you have been watching Kumagai GumiLtd lately, you have probably noticed its impressive run in the market. Over the past year, the stock has surged by 49.2%. Looking at a three-year period, the gain more than doubles to a striking 114.6%. Even in the shorter term, the momentum has not let up, with a 2.3% climb this week and a robust 23.4% return year-to-date. These kinds of returns naturally spark questions: is all the easy money gone, or could there be even more upside? Recently, investor...
SGX:G07
SGX:G07Insurance

Is Great Eastern Still a Bargain After Its 11% Surge and Sector Optimism in 2025?

If you have been following Great Eastern Holdings lately, you have probably noticed its stock catching more eyes on the market. With a last close at $15.31 and a year-to-date gain of 13.4%, plus an impressive 11.3% jump just in the past week, investors are clearly reacting to more than just routine headlines. Much of this momentum can be traced back to recent shifts across the insurance sector, with investors re-evaluating risk and growth in a changing economic landscape. There has been...
TASE:BEZQ
TASE:BEZQTelecom

Does Bezeq Offer More Value After Shares Jump 57% With FCF Outlook in 2025?

If you have ever found yourself eyeing Bezeq The Israel Telecommunication stock and wondering if now is the time to jump in, you are definitely not alone. Bezeq's reputation as an industry anchor in Israel means its moves, or lack of them, tend to attract plenty of attention from investors both local and abroad. Over the last year, Bezeq has pulled off a substantial gain of 57.2%, outpacing many expectations and rewarding those who stuck with it. The stock's climb of 19.4% year-to-date, along...
NasdaqCM:AIRE
NasdaqCM:AIRESoftware

Can reAlpha Tech’s (AIRE) AI Automation Drive a Lasting Edge in the Competitive Mortgage Space?

Earlier this week, reAlpha Tech Corp. announced an upgrade to its internal AI Loan Officer Assistant, enhancing mortgage automation by streamlining document classification, extraction, and validation for over 75 types of borrower documents using advanced OCR and generative AI. This latest advancement is designed to free loan officers from repetitive tasks, enabling more focus on advising borrowers and strengthening compliance oversight. We'll explore how this expanded AI integration and...
ENXTPA:BAIN
ENXTPA:BAINHospitality

Is There Room for Growth in Monte-Carlo SBM After a 7% Share Price Rise in 2025?

If you are weighing your options on Société Anonyme des Bains de Mer et du Cercle des Étrangers à Monaco, you are not alone. There is a lot to consider with this unique stock, especially for those looking at its place within Monaco's luxury and hospitality sector. The share price has been quietly on the move, with a 1.9% gain over the past week and 4.3% over the last month. Zoom out, and you will see a year-to-date climb of 7.4%, which stands in sharp contrast to the small dip of -1.8% over...
NasdaqGS:IAS
NasdaqGS:IASMedia

Profit Surge and Strong Insider Alignment Could Be a Game Changer for Integral Ad Science (IAS)

Integral Ad Science Holding recently reported strong annual earnings per share growth from US$0.018 to US$0.34, accompanied by higher EBIT margins and increased revenues. Company leadership's significant insider ownership, holding US$14 million in shares, highlights robust management-shareholder alignment and commitment to long-term value creation. We'll now explore how this improved profitability and management alignment could influence Integral Ad Science Holding’s investment narrative...
TSX:LIF
TSX:LIFMetals and Mining

Assessing Labrador Iron Ore Royalty Stock Amid Rising Iron Ore Prices in 2025

If you are wondering what to do with Labrador Iron Ore Royalty stock right now, you are definitely not alone. Over the past month, the share price has crept up 4.2%, building on a steady 2.5% gain in just the last week. While the one-year mark shows a modest 0.6% return, the longer-term picture is even more interesting. Over the last five years, the stock is up an impressive 78.9%, showing that those with patience have been handsomely rewarded. So, with these numbers in mind, is this a case...
NasdaqGS:GOSS
NasdaqGS:GOSSBiotechs

Could Gossamer Bio’s (GOSS) FDA Momentum Reshape Its Competitive Edge in Lung Disease Innovation?

In recent weeks, H.C. Wainwright reaffirmed a positive outlook on Gossamer Bio after its lead pulmonary arterial hypertension drug, seralutinib, delivered encouraging long-term results in the Phase 2 TORREY trial and drew optimism ahead of Phase 3 PROSERA data. This momentum has been further supported by promising FDA designations and Gossamer Bio’s active engagement in conferences, reflecting both industry attention and renewed interest in innovative lung disease treatments. We'll examine...
TSE:4536
TSE:4536Pharmaceuticals

Does Santen Offer Opportunity After Its Strong 77.9% Rise Over Three Years?

Trying to decide whether to buy, hold, or sell Santen Pharmaceutical? You are definitely not alone. The stock has attracted attention thanks to some eye-catching moves: a modest 0.3% bump last week, 2.8% up over the last month, and a respectable 1.0% gain since the start of the year. What also stands out is the rollercoaster of recent years. While Santen’s share price soared an impressive 77.9% over the last three years, it is still trailing its five-year mark by 13.6%. Clearly, perceptions...
NasdaqGS:REG
NasdaqGS:REGRetail REITs

Is Regency Centers Poised for Growth After Solid Q1 Leasing and Earnings in 2025?

Struggling with what to do about Regency Centers stock? You are not alone. With shares last closing at $71.34 and the stock logging a return of -2.4% in the past week, investors are watching closely for signs of which way things might move next. While the near-term numbers may feel a touch underwhelming, take a step back and the story gets much more interesting. Over the past five years, Regency Centers has surged 134.7%. Even the past three years have delivered a solid total gain of 36.9%...
NYSE:EVH
NYSE:EVHHealthcare Services

Should Investors Reassess Evolent Health After 70% Drop and Payment Model News in 2025?

Wondering what to do with Evolent Health stock after a wild ride in the market? You are not alone. The stock has turned heads in both directions lately, with a 6.7% dip over the past week and a 3% slip over the past month. If you have held on through the past year, it has been especially challenging, given a staggering 70.3% drop over that period. Even the longer-term returns, down 76.4% for three years and 21.6% over five years, may have shaken the confidence of even the most steadfast...
SEHK:728
SEHK:728Telecom

How the China Telecom Share Price Rally Stacks Up After New AI and Cloud Expansion Plans

If you are on the fence about what to do with China Telecom stock right now, you are not alone. Plenty of investors are watching this company closely after a run that has seen the share price deliver a stellar 229.7% gain over the past five years. Even after a flat week and a modest pullback of 9.3% over the past month, the long-term trend is very much intact, with 143.0% returns in three years and an eye-catching 39.6% gain in just the last year. Year-to-date, shares are up 21.9%, easily...
NasdaqGS:INDV
NasdaqGS:INDVPharmaceuticals

Is There Still Opportunity in Indivior After Its Impressive 143% Rally?

If you are weighing your options with Indivior, you are not alone in wondering whether now is the right time to get on board, hold steady, or lock in some gains. Indivior has made plenty of headlines with its impressive long-term performance. The stock has soared 143.3% over the past year and a staggering 211.5% over five years, turning patient investors into clear winners. Even so, the past month shows a mild pullback of -1.1%, and the last week has seen a sharper dip of -6.2%. These recent...
SEHK:322
SEHK:322Food

Is There Opportunity in Tingyi After 12% Share Price Climb and Partnership With Mengniu?

If you are weighing your next move on Tingyi (Cayman Islands) Holding, you are definitely not alone. With so many updates and shifts in the broader consumer staples sector, plenty of investors are revisiting this stock to decide if now is the right time to buy, sell, or simply hold on. Let us look at what has been happening: after a solid rise of 18.0% over the past five years, Tingyi's stock has climbed 12.2% year-to-date and 12.7% over the last year. The past month was a little quieter with...
NasdaqGM:DSY
NasdaqGM:DSYPersonal Products

Big Tree Cloud Holdings (NasdaqGM:DSY): Exploring Valuation After Insider-Driven Stock Surge and Newfound Market Attention

Big Tree Cloud Holdings (NasdaqGM:DSY) has suddenly captured attention after a massive jump in its stock value last week, with shares rising 172%. What has everyone talking is not just the rally itself, but the fact that insiders, especially CEO Wenquan Zhu, who owns a striking 88% of the company, have been the primary beneficiaries of this move. Minimal institutional involvement and scant analyst coverage mean this surge feels very much driven by those closest to the business, rather than...
ASX:SSM
ASX:SSMConstruction

A Look at Service Stream's (ASX:SSM) Valuation After Securing $1.6 Billion Defence Contract

If you’ve been tracking Service Stream (ASX:SSM), the $1.6 billion base services contract it just landed with the Australian Department of Defence is big news. This agreement covers 113 sites and training facilities over an initial six-year term and positions Service Stream to broaden its reach well beyond its traditional markets. For investors, this win clearly signals a major shift as the company moves further into the defence sector and secures stable, government-backed revenue streams for...
NasdaqGS:MLYS
NasdaqGS:MLYSBiotechs

Assessing Mineralys Therapeutics After Its 155% Surge and Strong Pipeline Developments

If you have been watching Mineralys Therapeutics lately, you are probably wondering just how much more it can deliver for your portfolio. The buzz is real, and so are the numbers. With a 155.5% surge over the past 30 days and a staggering 202.9% gain so far this year, Mineralys has certainly gotten investors’ attention. Its one-year return of 219.8% stands out not just in its sector, but across the broader market as well. Part of this momentum can be traced to growing optimism around...